Legal & General Group Plc grew its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 3.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 8,528 shares of the medical device company’s stock after purchasing an additional 312 shares during the period. Legal & General Group Plc’s holdings in AtriCure were worth $208,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ATRC. Wells Fargo & Company MN increased its stake in shares of AtriCure by 131.9% in the 1st quarter. Wells Fargo & Company MN now owns 112,006 shares of the medical device company’s stock valued at $2,145,000 after purchasing an additional 63,711 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of AtriCure by 24.2% in the 1st quarter. Bank of New York Mellon Corp now owns 179,586 shares of the medical device company’s stock valued at $3,439,000 after purchasing an additional 35,013 shares during the last quarter. Swiss National Bank increased its stake in shares of AtriCure by 7.0% in the 1st quarter. Swiss National Bank now owns 54,700 shares of the medical device company’s stock valued at $1,048,000 after purchasing an additional 3,600 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in shares of AtriCure by 11.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 34,622 shares of the medical device company’s stock valued at $663,000 after purchasing an additional 3,488 shares during the last quarter. Finally, American International Group Inc. increased its stake in shares of AtriCure by 7.0% in the 1st quarter. American International Group Inc. now owns 19,346 shares of the medical device company’s stock valued at $370,000 after purchasing an additional 1,273 shares during the last quarter. Institutional investors own 82.11% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/13/atricure-inc-atrc-stake-boosted-by-legal-general-group-plc.html.

In related news, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total value of $224,000.00. Following the transaction, the director now owns 29,967 shares of the company’s stock, valued at $671,260.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.00% of the stock is owned by corporate insiders.

Several equities analysts have recently issued reports on the company. Stifel Nicolaus reiterated a “buy” rating and issued a $25.00 price target on shares of AtriCure in a research note on Sunday, July 30th. BidaskClub lowered AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Canaccord Genuity reiterated a “buy” rating and issued a $28.00 price target on shares of AtriCure in a research note on Monday. Zacks Investment Research upgraded AtriCure from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $26.00 price target (up previously from $25.00) on shares of AtriCure in a research note on Friday, July 28th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $25.83.

Shares of AtriCure, Inc. (NASDAQ ATRC) opened at 22.40 on Friday. The company’s market cap is $769.08 million. The company’s 50-day moving average price is $21.82 and its 200-day moving average price is $21.88. AtriCure, Inc. has a 12 month low of $14.78 and a 12 month high of $25.18.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, July 27th. The medical device company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.05. The business had revenue of $45.23 million for the quarter, compared to analysts’ expectations of $44.15 million. AtriCure had a negative return on equity of 19.56% and a negative net margin of 19.56%. The firm’s revenue was up 14.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. Analysts anticipate that AtriCure, Inc. will post ($0.95) EPS for the current year.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Stock Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related stocks with our FREE daily email newsletter.